OPKO Health (NASDAQ:OPK) Share Price Drops 2.4%

Shares of OPKO Health, Inc. (NASDAQ:OPK – Get Free Report ) traded down 2.4% on Wednesday. The stock traded as high as $1.59 and last traded at $1.62. About 835,874 shares traded hands during trading, down 89% from the average daily volume of 7,738,476 shares. Shares previously closed at $1.66.

Analysts on Wall Street are forecasting an increase

A number of equities analysts have commented on the company. StockNews.com raised OPKO Health to a “sell” rating in a report on Saturday, July 27th. Piper Sandler restated an “overweight” rating and issued a $3.00 price objective on shares of OPKO Health in a report on Tuesday. Barrington Research boosted their target price on shares of OPKO Health from $1.50 to $2.25 and gave the stock an “outperform” rating in a report on Thursday, August 8th. Finally, HC Wainwright restated a “buy” rating and set a $3.00 price target on shares of OPKO Health in a research report on Tuesday.

Check out our latest OPKO health report

OPKO Health stock down 2.4%

The company’s fifty day simple moving average is $1.51 and two hundred day simple moving average is $1.32. The company has a market cap of $1.13 billion, a price-to-earnings ratio of -4.74 and a beta of 1.64. The company has a current ratio of 1.63, a quick ratio of 1.36, and a debt-to-equity ratio of 0.13.

OPKO Health (NASDAQ:OPK – Get Your Free Report ) last posted its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.08. The company had revenue of $182.20 million during the quarter, compared to analysts’ expectations of $184.70 million. OPKO Health had a negative return on equity of 17.67% and a negative net margin of 33.79%. The company’s quarterly revenue was down 31.3% compared to the same quarter last year. In the same quarter last year, the company earned ($0.03) earnings per share. Sell-side analysts anticipate that OPKO Health, Inc. will show -0.29 EPS for the current year.

Insider buying and selling at OPKO Health

In other news, major shareholder Opko Health, Inc. sold 14,082 shares of the company’s stock in a transaction dated Wednesday, July 3rd. The shares were sold at an average price of $28.23, for a total transaction of $397,534.86. Following the completion of the transaction, the insider now directly owns 3,469,521 shares in the company, valued at $97,944,577.83. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders have sold a total of 736,644 shares of company stock worth $23,874,134 over the last three months. Insiders own 47.26% of the company’s shares.

Institutional inputs and outputs

Several institutional investors and hedge funds have recently bought and sold shares of the stock. CIBC Asset Management Inc boosted its holdings in shares of OPKO Health by 79.1% in the second quarter. CIBC Asset Management Inc now owns 20,322 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 8,978 shares during the period. Hollencrest Capital Management lifted its position in OPKO Health by 14.0% in the 2nd quarter. Hollencrest Capital Management now owns 90,000 shares of the biotechnology company’s stock worth $112,000 after acquiring an additional 11,020 shares during the period . Price T Rowe Associates Inc. MD raised its stake in OPKO Health by 4.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 445,981 shares of the biotechnology company’s stock valued at $536,000 after buying an additional 17,671 shares during the last quarter. IPG Investment Advisors LLC purchased a new position in OPKO Health in the 4th quarter valued at $30,000. Finally, Virtu Financial LLC purchased a new position in OPKO Health in the first quarter valued at $26,000. 64.63% of shares are owned by institutional investors and hedge funds.

About OPKO Health

(Get a free report)

OPKO Health, Inc, a healthcare company, engages in diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico and internationally. The company’s Diagnostics segment operates BioReference Laboratories which provides laboratory testing services for the detection, diagnosis, evaluation, monitoring and treatment of diseases, including esoteric testing, molecular diagnostics, anatomic pathology, genetics, women’s health and correctional healthcare to medical offices, clinics. , hospitals, employers and government units; and the 4Kscore test for prostate cancer.

See Also

Get news and reviews for OPKO Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for OPKO Health and related companies with MarketBeat.com ‘s FREE daily email newsletter.